Analysis of pramipexole dose&amp;ndash;response relationships in Parkinson&amp;#39;s disease

Wang, Ying; Sun, Shan; Zhu, Suiqiang; Liu, Chunfeng; Liu, Yiming; Qin, Di; Shang, Huifang; Ren, Yan; Xiang, Wei; Chen, Shengdi

doi:10.2147/dddt.s112723

Cited by 8 publications

(6 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…6 Through a neuroprotective effect, pramipexole delays levodopa-induced motor complications in early PD, controls motor symptoms, and relieves depression in PD patients. 7 A recent study demonstrated that inflammatory cytokines are abnormally expressed in patients with neurodegenerative diseases and are involved in disease development. 8 Another study found that long-term overactivation of microglial cells in the brains of PD patients was associated with significantly increased levels of a large number of pro-inflammatory cytokines, including tumor necrosis factor (TNF)-a, interleukin (IL)-1b, IL-6, and interferon-c. 9 Although the outcomes of treatment with either pramipexole or levodopa alone for PD have been widely studied, the effect of combining pramipexole with levodopa on inflammatory cytokines and disease outcomes has not been adequately studied.…”

Section: Introductionmentioning

confidence: 99%

RETRACTED: Efficacy of pramipexole combined with levodopa for Parkinson’s disease treatment and their effects on QOL and serum TNF-α levels

et al. 2020

View full text Add to dashboard Cite

Purpose To investigate the efficacy of combining the dopamine receptor agonist pramipexole with levodopa for Parkinson’s disease (PD) treatment and to measure their effects on quality of life and tumor necrosis factor (TNF)-α levels in PD patients. Basic Procedure In total, 160 PD patients who were admitted to our hospital were equally randomized into a control treatment group (levodopa alone) and the study group (pramipexole combined with levodopa). Both groups were treated for 12 weeks. Findings After treatment, scores from the Unified Parkinson’s Disease Rating Scales (1–3), the Hamilton Depression Scale, and the Parkinson’s Disease Questionnaire (PDQ-39) were significantly decreased in both groups, whereas Mini-Mental State Examination scores were significantly increased. After treatment, the study group had significantly lower scores for all scales except the Mini-Mental State Examination, for which those who received combined treatment had significantly higher scores than the control group. The incidence of adverse reactions was significantly lower in the study group than in the control group. Furthermore, after treatment, serum TNF-α levels were significantly decreased in both groups compared with pre-treatment levels. Conclusion Pramipexole combined with levodopa relieved PD symptoms and improved the quality of life of PD patients, potentially by suppressing serum TNF-α levels.

show abstract

Section: Introductionmentioning

confidence: 99%

RETRACTED: Efficacy of pramipexole combined with levodopa for Parkinson’s disease treatment and their effects on QOL and serum TNF-α levels

et al. 2020

View full text Add to dashboard Cite

show abstract

“…After 3-years of treatment, in the same manner, motor and daily living tasks (UPDRS III scale) of the patients of PP cohort were also improved. The study results were parallel with the results of double-blind studies (11,12). Pramipexole may also delay the progression of disease in patients with confirmed Parkinson's disease.…”

Section: Expendituresupporting

confidence: 66%

Pramipexole Versus Selegiline in Patients with Parkinson’s Disease: An Effectiveness and Safety (EAS) Analysis

Tao

Chen

Xiao

et al. 2019

Iran Red Crescent Med J

View full text Add to dashboard Cite

Background: Levodopa treatment is the gold standard in Parkinson's disease but has the risk of dyskinesias. Selegiline delays the introduction of levodopa and pramipexole is used as a symptomatic treatment in Parkinson's disease. Objectives: This study aimed to compare the effectiveness of pramipexole with selegiline in Parkinson's disease patients. Methods: Data regarding motor and cognitive impairments and plasma phospholipids of 500 Chinese patients with confirmed Parkinson's disease from medical records of 1 January 2015 to 1 June 2016 were retrospectively evaluated. Patients received either pramipexole (PP cohort, n = 250) or selegiline (SG cohort, n = 250). Also, data regarding hospitalization, adverse effects, and expenditure were collected and analyzed from records of the follow-up period. Results: After 3-years of treatments, selegiline and pramipexole both improved motor and cognitive impairments and decreased plasma phospholipid levels (P < 0.05 for all). The intensity of improvement in motor and cognitive impairments and a decrease in the level of plasma phospholipids for pramipexole was higher than those of selegiline (P < 0.05 for all). Pramipexole caused muscle weakness (P = 0.015) and peripheral edema (P = 0.0004). While, selegiline caused cardiovascular disease (P = 0.008). Higher numbers of patients in the SG cohort were hospitalized during 3-years of treatment than those in PP cohort (11 vs. 1, P = 0.009). Selegiline treatment is more expensive than pramipexole (4,457 ± 345 ¥ vs. 3,649 ± 301 ¥/patient/year, P < 0.0001). Conclusions: Pramipexole treatment may have better improvement in motor and cognitive impairments than selegiline with neuroprotective action and manageable side effects (Level of Evidence: III).

show abstract

“…Our analysis found significant improvement in QoL among those who received the optimal maintenance dose of pramipexole (≥ 1.5 mg). Pramipexole 1.5 mg was determined as a critical dose since patients receiving ≥ 1.5 mg per day showed greater improvements in motor function and fewer adverse events than patients who received < 1.5 mg per day [ 21 ]. However, a daily dose lower than 1.5 mg has been reported in a previous clinical trial in China [ 40 ] and this remains a concern.…”

Section: Discussionmentioning

confidence: 99%

“…Additional exploratory subgroup meta-analyses were conducted after grouping selected studies according to: (i) pramipexole treatment dose: studies with ≥ 80% of patients receiving the recommended daily dose of ≥ 1.5 mg were categorised as “optimal dose” groups [ 20 , 21 ] and those with a daily dose < 1.5 mg were considered “low dose” groups; (ii) baseline disease stage: advanced or early PD, according to the disease severity of the respective original studies; (iii) baseline QoL level: the studies were grouped into high (≥ 25) or low (< 25) QoL groups according to the baseline total PDQ-39 mean scores.…”

Section: Methodsmentioning

confidence: 99%

Efficacy of pramipexole on quality of life in patients with Parkinson’s disease: a systematic review and meta-analysis

Zou

Zhang

et al. 2022

BMC Neurol

View full text Add to dashboard Cite

Background Quality of life (QoL) in patients with Parkinson’s disease (PD) is increasingly used as an efficacy outcome in clinical studies of PD to evaluate the impact of treatment from the patient’s perspective. Studies demonstrating the treatment effect of pramipexole on QoL remain inconclusive. This study aims to evaluate the effect of pramipexole on QoL in patients with PD by conducting a systematic review and meta-analysis of existing clinical trials. Methods A systematic literature search of PubMed, Embase and the Cochrane Library was performed from inception to 30 April 2022 to identify randomised, placebo-controlled trials of patients with idiopathic PD receiving pramipexole, who reported a change from baseline in their QoL as measured by the 39-item Parkinson’s Disease Questionnaire (PDQ-39). Risk of bias was independently assessed by two reviewers using the Cochrane Collaboration’s tool for bias assessment. Results Of 80 eligible articles screened, six trials consisting of at least 2000 patients with early or advanced PD were included. From the synthesis of all six selected trials, a significant mean change from baseline in the PDQ-39 total score of –2.49 (95% CI, –3.43 to –1.54; p < 0.0001) was observed with pramipexole compared with placebo. A trend toward improvement in QoL was consistently observed among patients who received optimal doses of pramipexole (≥ 80% of the study population on 1.5 mg dosage), regardless of disease severity (advanced versus early) or baseline QoL levels. Conclusion This meta-analysis provides evidence for the potential treatment benefit of pramipexole in improving QoL in patients with PD.

show abstract

Analysis of pramipexole dose–response relationships in Parkinson's disease

Cited by 8 publications

References 24 publications

RETRACTED: Efficacy of pramipexole combined with levodopa for Parkinson’s disease treatment and their effects on QOL and serum TNF-α levels

RETRACTED: Efficacy of pramipexole combined with levodopa for Parkinson’s disease treatment and their effects on QOL and serum TNF-α levels

Pramipexole Versus Selegiline in Patients with Parkinson’s Disease: An Effectiveness and Safety (EAS) Analysis

Efficacy of pramipexole on quality of life in patients with Parkinson’s disease: a systematic review and meta-analysis

Contact Info

Product

Resources

About